Search results
Results from the WOW.Com Content Network
Tablets of Truvada, a tenofovir/emtricitabine combination used for HIV pre-exposure prophylaxis. Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people that do not yet have HIV/AIDS. [1]
It was approved for PrEP against HIV infection in the United States in 2012. [17] The CDC recommends PrEP be considered for the following high-risk groups: [18] Individuals in an ongoing sexual relationship with an HIV-positive partner; Gay or bisexual men who either have had anal sex without a condom or been diagnosed with an STD in the past ...
The abbreviation PrEP now typically refers to pre-exposure prophylaxis for HIV prevention, the use of antiviral drugs as a strategy for the prevention of HIV/AIDS. [2] PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active adults at increased risk of contracting HIV, people who engage in ...
Experts say breakthrough HIV should still remain rare in those receiving ViiV Healthcare’s injectable Apretude as PrEP, an alternative to Truvada and Descovy.
Common side effects include headaches, fever, and nausea. [6] Serious side effects include liver problems, muscle damage, and high blood lactate levels. [6] It is commonly used in pregnancy and appears to be safe for the fetus. [6] ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. [6]
Truvada is already used to treat HIV and also in a prevention regimen known as pre-exposure prophylaxis (PrEP). More than one-third of people in the U.S. who could benefit from PrEP had been ...
The most commonly reported side effects due to use of tenofovir disoproxil were dizziness, nausea, and diarrhea. [13] Other adverse effects include depression, sleep disturbances, headache, itching, rash, and fever. The US boxed warning cautions potential onset of lactic acidosis or liver damage due to use of tenofovir disoproxil. [14]
HIV vaccine development is an active area of research and an important tool for managing the global AIDS epidemic. Research into a vaccine for HIV has been ongoing for decades with no lasting success for preventing infection. [151] The rapid development, though, of mRNA vaccines to deal with the COVID-19 pandemic may provide a new path forward.